Evaluation of a Minimally Invasive Cell Sampling Device Coupled with Assessment of Trefoil Factor 3 Expression for Diagnosing Barrett's Esophagus: A Multi-Center Case–Control StudyCaryn S. Ross-Innes, Philip Kaye, Marco Novelli et al.|PLoS Medicine|2015Cited by 301
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trialDavid Cunningham, Ruth E. Langley, Sally Stenning et al.|The Lancet Oncology|2017Cited by 286
Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trialDerek Alderson, Ruth E. Langley, David Cunningham et al.|The Lancet Oncology|2017Cited by 223
Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: Results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072).Derek Alderson, David Cunningham, Ruth E. Langley et al.|Journal of Clinical Oncology|2015Cited by 80
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety reportAlicia Okines, David Cunningham, Ruth E. Langley et al.|Annals of Oncology|2012Cited by 67